Skip to main
MET

MetLife (MET) Stock Forecast & Price Target

MetLife (MET) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 33%
Buy 58%
Hold 8%
Sell 0%
Strong Sell 0%

Bulls say

MetLife is a well-established, diversified insurance company with a strong financial footing and a focus on capital-light, high return business segments. Their expansion in the Latin American market, where they are considered the top life insurer, presents significant growth potential in a region with strong demand for protection and group benefits products. MetLife also benefits from their diverse product suite and high persistency ratio in their Group Benefits segment, making them a one-stop-shop and providing consistent revenue. However, their global presence does expose them to potential geopolitical and international risks. Overall, we believe the company's strategic execution in recent years qualifies them as a premium player in the insurance space and justifies a higher valuation, leading us to upgrade our outlook to Overweight with an expected increase in earnings and EPS for 2026 and 2027. At the same time, we remain cautious due to potential market volatility and the uncertainty of variable investment income's impact on their earnings growth targets.

Bears say

MetLife is a well-established, consistent grower in the life insurance industry, however, their valuation and future prospects do not warrant trading at the same multiples as their higher valued peers like Aflac, Globe Life, Unum, and Principal. Additionally, they face competitive pressures from other global life insurance companies and are at risk from changes in interest rates and credit spreads, which could affect their investment portfolio and profitability. Lastly, while their guidance for variable investment income looks promising, it is one of the few sources of earnings volatility and may not be enough to outweigh the potential risks and challenges facing the company.

MetLife (MET) has been analyzed by 12 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 58% recommend Buy, 8% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MetLife and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MetLife (MET) Forecast

Analysts have given MetLife (MET) a Buy based on their latest research and market trends.

According to 12 analysts, MetLife (MET) has a Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $105, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $105, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MetLife (MET)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.